Viyash Scientific Ltd Upgraded to Hold as Technicals and Financials Improve

Technical Indicators Shift to Bullish Momentum

The primary catalyst for the rating upgrade is the marked improvement in Viyash Scientific’s technical profile. The technical trend has shifted from a sideways pattern to a bullish trajectory, signalling growing investor confidence and positive price momentum. Key technical indicators underpinning this shift include a bullish Moving Average Convergence Divergence (MACD) on both weekly and monthly charts, alongside bullish Bollinger Bands over the same periods.

Daily moving averages have also turned bullish, reinforcing the positive momentum in the short term. The Know Sure Thing (KST) indicator is mildly bullish on a weekly basis and bullish monthly, while Dow Theory assessments show a mildly bullish trend monthly, though weekly trends remain neutral. On-balance volume (OBV) metrics indicate mild bullishness monthly but no clear trend weekly, suggesting volume support is gradually strengthening.

This technical upgrade is reflected in the stock’s recent price action, with the current price at ₹225.30, up 2.88% on the day, and a 52-week high of ₹260.30. The stock has outperformed the Sensex significantly, delivering a 10.09% return over the past week compared to the Sensex’s decline of 1.62%, and a 40.07% return over the last year versus the Sensex’s 4.33% loss.

Financial Trend: Exceptional Quarterly Performance

Viyash Scientific’s financial trend has been a strong contributor to the upgrade. The company reported an outstanding operating profit growth of 78.2% in Q3 FY25-26, with profit before tax excluding other income (PBT LESS OI) soaring by 384.55% to ₹100.35 crores. This marks the eighth consecutive quarter of positive results, underscoring a sustained improvement in operational efficiency and profitability.

Return on Capital Employed (ROCE) for the half-year period reached a high of 18.65%, a significant improvement over the company’s long-term average of 7.40%. The operating profit to interest ratio also hit a peak of 10.49 times, indicating a strong ability to service debt and manage financial obligations effectively.

Despite these impressive quarterly results, the company’s long-term fundamentals remain mixed. Over the past five years, net sales have grown at a modest annual rate of 14.17%, while operating profit growth averaged 12.25%. The debt to EBITDA ratio stands at 1.32 times, reflecting a moderate level of leverage that investors should monitor.

Valuation: Expensive Yet Discounted Relative to Peers

Valuation metrics present a nuanced picture. Viyash Scientific’s ROCE of 18.1% is accompanied by an enterprise value to capital employed ratio of 8.4, suggesting the stock is relatively expensive on a standalone basis. However, when compared to its pharmaceutical and biotechnology peers, the stock trades at a discount to their average historical valuations, offering some value to investors.

The company’s price-to-earnings-to-growth (PEG) ratio stands at 1.8, reflecting a premium valuation justified by the rapid profit growth of 138.8% over the past year. This premium is supported by the stock’s consistent outperformance of the BSE500 index in each of the last three annual periods, delivering 40.07% returns in the last year alone.

Quality Assessment: Mixed Long-Term Fundamentals

While the recent financial and technical improvements are encouraging, the quality of Viyash Scientific’s long-term fundamentals remains a concern. The company’s average ROCE over the last five years is relatively weak at 7.40%, and its sales growth, though positive, is moderate. The high debt to EBITDA ratio of 1.32 times also signals some risk in financial stability over the longer term.

Promoters remain the majority shareholders, which typically provides stability and alignment of interests. However, investors should weigh the company’s strong recent momentum against these underlying fundamental challenges.

Comparative Returns and Market Context

Viyash Scientific’s stock performance has been impressive relative to the broader market. Over the last three years, the stock has generated a cumulative return of 186.39%, vastly outperforming the Sensex’s 22.79% gain. Even over the last year, the stock’s 40.07% return contrasts sharply with the Sensex’s 4.33% decline.

However, over a five-year horizon, the stock has underperformed, delivering a negative return of 21.51% compared to the Sensex’s 54.62% gain. This highlights the stock’s volatility and the importance of timing in investment decisions.

In the short term, the stock’s weekly and monthly returns remain robust, with 10.09% and 7.77% gains respectively, while the Sensex has declined over the same periods. This recent outperformance aligns with the technical upgrade and strong quarterly results, supporting the revised Hold rating.

Conclusion: A Balanced Hold Recommendation

Viyash Scientific Ltd’s upgrade from Sell to Hold reflects a balanced assessment of its current strengths and weaknesses. The company’s technical indicators have turned decisively bullish, supported by exceptional quarterly financial performance and consistent returns that have outpaced the market in recent years.

Nevertheless, investors should remain cautious given the company’s mixed long-term fundamentals, moderate sales growth, and relatively high valuation metrics. The Hold rating suggests that while the stock is no longer a sell, it may not yet warrant a Buy recommendation until further improvements in fundamentals and valuation are realised.

For investors seeking exposure to the pharmaceuticals and biotechnology sector, Viyash Scientific offers a compelling case for inclusion on a watchlist, particularly for those who prioritise momentum and recent earnings strength. However, a thorough comparison with peers and alternative investment opportunities remains advisable.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today